Sangamo Therapeutics Inc (SGMO) VP Sells $68,650.00 in Stock

Sangamo Therapeutics Inc (NASDAQ:SGMO) VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $13.73, for a total transaction of $68,650.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Edward R. Conner also recently made the following trade(s):

  • On Monday, October 8th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $14.55, for a total transaction of $72,750.00.
  • On Thursday, September 6th, Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $14.17, for a total transaction of $70,850.00.

SGMO opened at $11.16 on Friday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 7.24 and a current ratio of 7.24. Sangamo Therapeutics Inc has a twelve month low of $11.02 and a twelve month high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.02. The company had revenue of $23.56 million during the quarter, compared to analysts’ expectations of $26.96 million. Sangamo Therapeutics had a negative net margin of 105.65% and a negative return on equity of 26.36%. Sangamo Therapeutics’s revenue for the quarter was up 99.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.15) earnings per share. As a group, analysts anticipate that Sangamo Therapeutics Inc will post -0.69 EPS for the current year.

SGMO has been the subject of several recent research reports. Wedbush reiterated a “hold” rating and issued a $9.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, July 24th. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 10th. ValuEngine downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. Finally, BidaskClub downgraded shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, October 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $21.00.

Large investors have recently modified their holdings of the stock. United Services Automobile Association grew its stake in Sangamo Therapeutics by 9.2% during the second quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock valued at $818,000 after acquiring an additional 4,860 shares in the last quarter. Wells Fargo & Company MN grew its stake in Sangamo Therapeutics by 42.2% during the second quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock valued at $11,218,000 after acquiring an additional 234,346 shares in the last quarter. Schwab Charles Investment Management Inc. grew its stake in Sangamo Therapeutics by 14.4% during the second quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock valued at $8,032,000 after acquiring an additional 71,134 shares in the last quarter. Platinum Investment Management Ltd. purchased a new position in Sangamo Therapeutics during the second quarter valued at approximately $751,000. Finally, Bain Capital Public Equity Management LLC purchased a new position in Sangamo Therapeutics during the second quarter valued at approximately $2,002,000. 64.01% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Sangamo Therapeutics Inc (SGMO) VP Sells $68,650.00 in Stock” was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://transcriptdaily.com/2018/11/10/sangamo-therapeutics-inc-sgmo-vp-sells-68650-00-in-stock.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: Hedge Funds – Risk or Reward?

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply